

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

[NLF](#)

RRID:CVCL_E217

Type: Cell Line

Proper Citation

RRID:CVCL_E217

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_E217

Proper Citation: RRID:CVCL_E217

Description: Cell line NLF is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:6888561](#), [PMID:11550280](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:18724359](#), [PMID:23202128](#), [PMID:24466371](#), [PMID:25730103](#), [PMID:28350380](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NLF

Synonyms: NLF-Trk-NULL

Cross References: Cosmic:697276, Cosmic:717423, Cosmic:848928, Cosmic:923824, Cosmic:930072, Cosmic:1019953, Cosmic:1162000, Cosmic:1526638, Cosmic:2393639, GEO:GSM2371250, GEO:GSM2394370, GEO:GSM3145565, GEO:GSM3145727, Kerafast:ECP008, Wikidata:Q54930689

ID: CVCL_E217

Record Creation Time: 20220427T221344+0000

Record Last Update: 20260913T005622+0000

Ratings and Alerts

No rating or validation information has been found for NLF.

No alerts have been found for NLF.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. Molecular cancer therapeutics, 25(4), 635.

Lee JY, et al. (2023) Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. Cell reports. Medicine, 4(6), 101091.

Stokes ME, et al. (2023) Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers. Cell chemical biology.

Modi A, et al. (2023) Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors. Cancer research, 83(20), 3462.

Loh AHP, et al. (2022) Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse. Frontiers in oncology, 12, 939460.

Bosse KR, et al. (2022) Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. Cancer discovery, 12(12), 2800.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. International journal of cancer, 148(5), 1219.

Ghandi M, et al. (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 569(7757), 503.

Coggins GE, et al. (2019) YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling. Cancer research, 79(24), 6204.

Bosse KR, et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer cell, 32(3), 295.